Candel Therapeutics   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Auburndale MA United States (1999)

Organization Overview

First Clinical Trial
2005
NCT00751270
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Advantagene, Inc. | Candel Therapeutics, Inc.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 2)

Astrocytoma (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Ependymoma (Phase 1)

Glioblastoma (Phase 2)

Glioma (Phase 2)

Lung Neoplasms (Phase 2)

Mesothelioma (Phase 1)

Pancreatic Neoplasms (Phase 1)

Pleural Effusion (Phase 1)

Pleural Effusion, Malignant (Phase 1)

Prostatic Neoplasms (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 11
  • # of Trial APIs: 11